THe National Institutes of Health
(NIH), 10 biopharmaceutical
companies and several nonprofit
organisations have joined forces
to speed up validation of disease
targets.
The Accelerating Medicines
Partnership (AMP) will distinguish
biological disease targets most
likely to respond to new therapies
and characterise biomarkers.
The AMP partners, who include
GlaxoSmithKline, Pfizer and Sanofi,
will invest more than US$230m
over five years in the first projects,
focusing on Alzheimer’s Disease
and type 2 diabetes among others.
NIH said a critical element of the
partnership was the agreement
that data and analyses would be
made publicly available to the
biomedical community.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Feb 14
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
INTERN pharmacists from Monash University are set to join Victoria’s immunisation workforce under a new Secretary Approval by the Victorian Health Department.
VIRTUAL care delivered through telephone or video conference has now embedded itself as a core component of healthcare delivery in NSW, new market reports released today have revealed.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.